Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 532

1.

Deferasirox.

Stumpf JL.

Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. Review.

PMID:
17353569
2.

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

Shashaty G, Frankewich R, Chakraborti T, Choudary J, Al-Fayoumi S, Kacuba A, Castillo S, Robie-Suh K, Rieves D, Weiss K, Pazdur R.

Oncology (Williston Park). 2006 Dec;20(14):1799-1806, 1811; discussion 1811-13, 1817.

PMID:
17263129
3.

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.

Cappellini MD, Taher A.

Expert Opin Pharmacother. 2008 Sep;9(13):2391-402. doi: 10.1517/14656566.9.13.2391 . Review.

PMID:
18710363
4.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Review.

PMID:
20687088
5.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators.

Br J Haematol. 2007 Feb;136(3):501-8.

6.

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.

Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11.

PMID:
18408362
7.

Deferasirox for transfusion-related iron overload: a clinical review.

Lindsey WT, Olin BR.

Clin Ther. 2007 Oct;29(10):2154-66. Review.

PMID:
18042472
8.

Deferasirox for managing iron overload in people with thalassaemia.

Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.

Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476. doi: 10.1002/14651858.CD007476.pub3. Review.

PMID:
28809446
9.

Deferasirox--an oral agent for chronic iron overload.

Vanorden HE, Hagemann TM.

Ann Pharmacother. 2006 Jun;40(6):1110-7. Epub 2006 May 30. Review.

PMID:
16735647
10.

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.

Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Review.

11.

Deferasirox for managing iron overload in people with thalassaemia.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476. doi: 10.1002/14651858.CD007476.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476.

PMID:
22336831
12.

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D.

Haematologica. 2006 Jul;91(7):873-80.

13.

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.

Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19.

14.

Recent developments in iron chelation therapy.

Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.

Klin Padiatr. 2007 May-Jun;219(3):158-65. Review.

PMID:
17525910
15.

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.

Clin Ther. 2007 May;29(5):909-17.

PMID:
17697909
16.

Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.

Imran F, Phatak P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):297-304. doi: 10.1586/erp.09.26.

PMID:
19670988
17.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
18.

How I treat transfusional iron overload.

Hoffbrand AV, Taher A, Cappellini MD.

Blood. 2012 Nov 1;120(18):3657-69. doi: 10.1182/blood-2012-05-370098. Epub 2012 Aug 23.

19.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.

Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Review.

PMID:
23963793
20.

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.

Taher AT, Temraz S, Cappellini MD.

Expert Rev Hematol. 2013 Oct;6(5):495-509. doi: 10.1586/17474086.2013.827411. Epub 2013 Oct 2. Review.

PMID:
24083402

Supplemental Content

Support Center